The relevance of EZH2 in human prostate cancers is first evident by the finding that expression of EZH2 is highly upregulated in metastatic CRPC relative to the benign prostatic tissues and primary PCa [2]. This evidence concerns the gene EZH2 and posterior cortical atrophy.